
## Ediz Dalkilic

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1746661/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Characteristics Predicting Tuberculosis Risk under Tumor Necrosis Factor-α Inhibitors: Report from a Large Multicenter Cohort with High Background Prevalence. Journal of Rheumatology, 2016, 43, 524-529.	2.0	67
2	Incidence of Cyclophosphamide-induced Urotoxicity and Protective Effect of Mesna in Rheumatic Diseases. Journal of Rheumatology, 2015, 42, 1661-1666.	2.0	43
3	Genome-wide association study in Turkish and Iranian populations identify rare familial Mediterranean fever gene (MEFV) polymorphisms associated with ankylosing spondylitis. PLoS Genetics, 2019, 15, e1008038.	3.5	41
4	Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study. American Journal of Human Genetics, 2021, 108, 84-99.	6.2	26
5	Axial psoriatic arthritis: the impact of underdiagnosed disease on outcomes in real life. Clinical Rheumatology, 2018, 37, 3443-3448.	2.2	24
6	Comparing femaleâ€based contraceptive methods in patients with systemic lupus erythematosus, rheumatoid arthritis and a healthy population. International Journal of Rheumatic Diseases, 2014, 17, 653-657.	1.9	14
7	Methotrexate intoxication: Beyond the adverse events. International Journal of Rheumatic Diseases, 2018, 21, 1557-1562.	1.9	12
8	Uveitis-related Factors in Patients With Spondyloarthritis: TReasure Real-Life Results. American Journal of Ophthalmology, 2021, 228, 58-64.	3.3	10
9	Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Modern Rheumatology, 2012, 22, 738-742.	1.8	8
10	A successful pregnancy in a patient with Takayasu's arteritis under tocilizumab treatment: A longitudinal case study. International Journal of Rheumatic Diseases, 2019, 22, 1941-1944.	1.9	8
11	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	8
12	The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Modern Rheumatology, 2013, 23, 525-528.	1.8	7
13	lsotretinoin-induced sacroiliitis in patients with hidradenitis suppurativa: a case-based review. Rheumatology International, 2019, 39, 2159-2165.	3.0	7
14	Predictors for the risk and severity of post-thrombotic syndrome in vascular Behçet's disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2021, 9, 1451-1459.	1.6	7
15	Current Smoking Is Increased in Axial Psoriatic Arthritis and Radiographic Sacroiliitis. Journal of Rheumatology, 2020, 47, 1354-1358.	2.0	6
16	Preferences of inflammatory arthritis patients for biological disease-modifying antirheumatic drugs in the first 100 days of the COVID-19 pandemic. Turkish Journal of Medical Sciences, 2021, 51, 1615-1623.	0.9	6
17	Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Modern Rheumatology, 2012, 22, 463-466.	1.8	5
18	The time course of gastric methotrexate intolerance in patients with rheumatoid arthritis and psoriatic arthritis. Modern Rheumatology, 2013, 23, 525-528.	1.8	5

Ediz Dalkilic

#	Article	IF	CITATIONS
19	PsART-ID inception cohort: clinical characteristics, treatment choices and outcomes of patients with psoriatic arthritis. Rheumatology, 2021, 60, 1755-1762.	1.9	4
20	Real-world data on change in work productivity, activity impairment, and quality of life in patients with psoriatic arthritis under anti-TNF therapy: a postmarketing, noninterventional, observational study. Clinical Rheumatology, 2022, 41, 85-94.	2.2	4
21	Rituximab as a new therapeutic option in granulomatosis with polyangiitis: a report of two cases. Modern Rheumatology, 2012, 22, 463-466.	1.8	4
22	Evaluation of rheumatoid arthritis and connective tissue disease-related interstitial lung disease with pulmonary physiologic test, HRCT, and patient-based measures of dyspnea and functional disability. Clinical Rheumatology, 2021, 40, 3797-3805.	2.2	3
23	Attitudes of patients with a rheumatic disease on drug use in the COVID-19 pandemic. Advances in Rheumatology, 2021, 61, 55.	1.7	3
24	Tumor necrosis factor-alpha antagonist therapy-induced psoriasis in Turkey: analysis of 514 patients. Modern Rheumatology, 2012, 22, 738-742.	1.8	3
25	Anti-cyclic citrullinated peptide and rheumatoid factor in patients with chronic hepatitis B and hepatitis B carriers. European Journal of Rheumatology, 2015, 2, 62-65.	0.6	3
26	Ki-67 proliferation index in renal biopsy samples of patients with systemic lupus erythematosus and its correlation with clinical findings. Iranian Journal of Kidney Diseases, 2013, 7, 198-203.	0.1	3
27	What are the main barriers to achieve minimal disease activity in psoriatic arthritis in real life?. Clinical and Experimental Rheumatology, 2019, 37, 808-812.	0.8	3
28	Patients' concerns regarding biological agents in rheumatology. International Journal of Rheumatic Diseases, 2018, 21, 1219-1226.	1.9	2
29	Rheumatology patients' attitude regarding Ramadan and fasting. International Journal of Rheumatic Diseases, 2020, 23, 1082-1087.	1.9	2
30	In the era of disease-modifying antirheumatic drugs, how close are we to treating rheumatoid arthritis without the use of glucocorticoids?. Rheumatology International, 2021, 41, 1915-1924.	3.0	1
31	Disease characteristics of psoriatic arthritis patients may differ according to age at psoriasis onset: cross-sectional data from the Psoriatic Arthritis-International Database. Clinical and Experimental Rheumatology, 2021, 39, 532-536.	0.8	0
32	Tuberculin skin test before biologic and targeted therapies: does the same rule apply for all?. Rheumatology International, 2022, 42, 1797-1806.	3.0	0